The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II SBIR Grant With the Title “A Novel Therapeutic for Invasive Candidiasis”

 

Doylestown, PA. June 16, 2014- FCCDC is pleased to announce that it has been awarded a Phase II SBIR grant (R44 AI106270), with the title “A Novel Therapeutic for Invasive Candidiasis” ($750,000/yr/2 yrs).